CNS PHARMACEUTICALS INC (CNSP) Stock Price, Quote, News and Overview
NASDAQ:CNSP - Nasdaq - US18978H4092 - Common Stock - Currency: USD
CNSP Quote, Performance and Key Statistics
NASDAQ:CNSP (5/21/2025, 12:56:52 PM)
1.2856
0 (-0.34%)
The current stock price of CNSP is 1.2856 USD. In the past month the price increased by 44.62%. In the past year, price decreased by -99.75%.
CNSP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 53.35 | 695.93B | ||
| JNJ | JOHNSON & JOHNSON | 15.33 | 370.70B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.89 | 307.23B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.64 | 223.80B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.91 | 218.14B | ||
| MRK | MERCK & CO. INC. | 10.01 | 196.23B | ||
| PFE | PFIZER INC | 7.28 | 132.57B | ||
| SNY | SANOFI-ADR | 13.96 | 130.16B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.48 | 96.76B | ||
| GSK | GSK PLC-SPON ADR | 7.07 | 78.35B | ||
| ZTS | ZOETIS INC | 27.08 | 72.71B | ||
| HLN | HALEON PLC-ADR | 22.69 | 50.14B |
Related stock screener links
About CNSP
Company Profile
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Company Info
CNS PHARMACEUTICALS INC
2100 West Loop S Ste 900
Houston TEXAS 77027 US
CEO: John Climaco
Employees: 5
Phone: 18009469185
CNS PHARMACEUTICALS INC / CNSP FAQ
What is the stock price of CNS PHARMACEUTICALS INC today?
The current stock price of CNSP is 1.2856 USD. The price decreased by -0.34% in the last trading session.
What is the ticker symbol for CNS PHARMACEUTICALS INC stock?
The exchange symbol of CNS PHARMACEUTICALS INC is CNSP and it is listed on the Nasdaq exchange.
On which exchange is CNSP stock listed?
CNSP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CNS PHARMACEUTICALS INC stock?
8 analysts have analysed CNSP and the average price target is 204 USD. This implies a price increase of 15768.08% is expected in the next year compared to the current price of 1.2856. Check the CNS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CNS PHARMACEUTICALS INC worth?
CNS PHARMACEUTICALS INC (CNSP) has a market capitalization of 3.78M USD. This makes CNSP a Nano Cap stock.
How many employees does CNS PHARMACEUTICALS INC have?
CNS PHARMACEUTICALS INC (CNSP) currently has 5 employees.
What are the support and resistance levels for CNS PHARMACEUTICALS INC (CNSP) stock?
CNS PHARMACEUTICALS INC (CNSP) has a resistance level at 1.3. Check the full technical report for a detailed analysis of CNSP support and resistance levels.
Should I buy CNS PHARMACEUTICALS INC (CNSP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNSP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNSP, evaluating the profitability, health, valuation and growth aspects
- CNS PHARMACEUTICALS INC (CNSP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CNS PHARMACEUTICALS INC (CNSP) Sales and EPS estimates to see what analysts future expectations are.
- CNS PHARMACEUTICALS INC (CNSP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CNS PHARMACEUTICALS INC (CNSP) Insider and Institutional Ownership to learn about the owners and their transactions.
- CNS PHARMACEUTICALS INC (CNSP) Stock Chart to make your own analysis
- CNS PHARMACEUTICALS INC (CNSP) Latest news and press-releases to stay up to date.
Does CNS PHARMACEUTICALS INC (CNSP) stock pay dividends?
CNSP does not pay a dividend.
When does CNS PHARMACEUTICALS INC (CNSP) report earnings?
CNS PHARMACEUTICALS INC (CNSP) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of CNS PHARMACEUTICALS INC (CNSP)?
CNS PHARMACEUTICALS INC (CNSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-40500).
What is the Short Interest ratio of CNS PHARMACEUTICALS INC (CNSP) stock?
The outstanding short interest for CNS PHARMACEUTICALS INC (CNSP) is 21.5% of its float. Check the ownership tab for more information on the CNSP short interest.
CNSP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CNSP. When comparing the yearly performance of all stocks, CNSP is a bad performer in the overall market: 99.21% of all stocks are doing better.
CNSP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNSP. The financial health of CNSP is average, but there are quite some concerns on its profitability.
CNSP Financial Highlights
Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -40500. The EPS increased by 5.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -170.76% | ||
| ROE | -240.55% | ||
| Debt/Equity | 0.05 |
CNSP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CNSP. The Buy consensus is the average rating of analysts ratings from 8 analysts.